

Market Release

16 February 2024

Appendix 3Y – Nicholas England

PharmX Technologies Limited (ASX:PHX) (Company)

Chairman Nicholas England purchased PHX securities on market on 12 February 2024. An Appendix 3Y in relation to this share transaction is attached below.

The transaction took place during a closed period during which no trading is permitted under the Company's Securities Trading Policy (**Policy**). Mr England did not obtain the prior approval of the remaining Board members before making the trade. The Company considers the transaction as an inadvertent breach of the Policy by Mr England and believes that the breach does not warrant any disciplinary or remedial action. Mr England has advised the Board of the breach and apologised for his oversight. The Board is satisfied that Mr England's actions were due to a genuine oversight and an honest mistake.

Mr England has undertaken to fully comply with the Policy in respect of any transactions involving the Company's securities in the future. The Company considers that their current arrangements under the Policy are adequate and enforced.

The Company confirms that Mr England was not in possession of any price-sensitive information at the time of the transaction and therefore no insider trading on the part of Mr England occurred.

The Company further notes that:

- a) Mr England only purchased a small number of shares; and
- b) Mr England has not sold any shares in the Company since the transaction.

The Company confirms that it is complying with the Listing Rules, and in particular, Listing Rule 3.1

- ENDS -

This announcement is authorised for release by the Chairman of the Board of PharmX Technologies Limited.

For further information contact:

Tom Culver, Chief Executive Officer
Tom.Culver@pharmx.com.au

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	PharmX Technologies Ltd
ABN	25 000 091 305

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Philip Nicholas England
Date of last notice	30 November 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mersault Pty Ltd <The England Super Fund A/C> Mr England is a director of Mersault Pty Ltd
Date of change	12 February 2024
No. of securities held prior to change	26,853,334 fully paid ordinary shares (Shares)
Class	Shares
Number acquired	127,500 Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.015 per Share
No. of securities held after change	26,980,834 Shares

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Purchase of shares on-market
---	------------------------------

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Prior written clearance was not obtained under the share trading policy.
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

For personal use only